Kyntra Bio (KYNB) Total Liabilities (2014 - 2026)

Kyntra Bio has disclosed Total Liabilities across 13 years of filings, most recently posting $109.2 million for Q2 2026.

• In Q2 2026, Total Liabilities fell 69.58% year-over-year to $109.2 million; the TTM figure through Jun 2026 stood at $109.2 million (down 69.58% YoY), while the FY2025 annual figure was $115.1 million, down 71.09% from the prior year.
• Total Liabilities came in at $109.2 million for Q2 2026 at Kyntra Bio, down from $118.9 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $611.6 million in Q4 2022 to a low of $109.2 million in Q2 2026.
• Average Total Liabilities over 5 years is $426.2 million, with a median of $517.8 million recorded in 2024.
• Year-over-year, Total Liabilities soared 43.04% in 2022 and slumped 74.36% in 2025.
• Over 5 years, Total Liabilities stood at $611.6 million in 2022, then declined by 4.23% to $585.7 million in 2023, then tumbled by 32.02% to $398.2 million in 2024, then sank by 71.09% to $115.1 million in 2025, then fell by 5.12% to $109.2 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $109.2 million in Q2 2026, $118.9 million in Q1 2026, and $115.1 million in Q4 2025.